PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma
Clinical trial NCT07511036 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07511036
- Sponsor
- M.D. Anderson Cancer Center
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-09-01
- Primary completion
- 2028-05-24
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.